Extended Use of Sodium Bicarbonate in Patients With Cancer

Inclusion criteria

* Any cancer patient enrolled in the study must have a written approval from their oncologist that a notation will be made in the patient's chart for their study participation * Subject without known cognitive impairment, central nervous system (CNS) metastasis, overt psychosis, major depression, or delirium as noted in the oncology medical record * Subject with a Karnofsky performance status scale of 80% or greater at time of consent * Subject has completed initial adjuvant therapy and is not currently receiving or waiting to receive chemotherapy during the next 120 days * Breast cancer subjects may be enrolled if they are receiving hormonal blockade therapy * Subject is not enrolled in any other clinical trials * Subject has a valid working phone number to be contacted with during the study * Subject must be willing to provide urine specimen for pH measurements during scheduled clinical visits * Subject must be willing to provide a 3 mL blood sample for metabolic panels during scheduled clinical visits * Subject does not have uncontrolled hypertension (systolic pressure \> 140, diastolic pressure \> 90) despite maximal anti-hypertensive therapy * Subject has healthy renal function: creatinine clearance: 88-128 mL/min; glomerular filtration rate (GFR): \> 90 mL/min/1.7m\^2 based on standard care results no older than 2 weeks; if no data exist, the subject will need to consent to a blood draw for a basic metabolic panel (which measures creatinine) for verification * Subject must be informed of the investigational nature of this study and must sign and written informed consent in accordance with institutional and federal guidelines * Subject is not pregnant or breastfeeding at time of consent; a pregnancy test will be conducted from urine sample on day of consent in premenopausal women * Subject agrees to use medically approved contraception (ie. condoms, oral contraceptive) if premenopausal